Aphaia Pharma is a clinical-stage biopharmaceutical company harnessing proprietary precision-targeted drug delivery technology to restore endogenous endocrine balance for the treatment and prevention of metabolic disorders such as obesity and associated diseases. Aphaia’s lead candidate, APH-012 has shown to safely restore endocrine balance and improve metabolic health in individuals with obesity. APH-012 is being evaluated in a Phase 2 trial in the U.S. and Germany for chronic weight management and is preparing to be evaluated in a second Phase 2 trial for type 2 pre-diabetes improvement and prevention in individuals with pathological oral glucose tolerance test (OGTT). The versatile design of Aphaia’s technology platform provides an opportunity for the development of treatments for multiple metabolic disease